Loading clinical trials...
Loading clinical trials...
Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005
Conditions
Interventions
Dasatinib
Dasatinib
+1 more
Locations
13
Austria
Local Institution
Vienna, Austria
Local Institution
Nantes, France
Local Institution
Paris, France
Local Institution
Paris, France
Local Institution
Berlin, Germany
Local Institution
Frankfurt, Germany
Start Date
March 31, 2006
Primary Completion Date
May 31, 2011
Completion Date
May 22, 2019
Last Updated
February 26, 2021
NCT06285890
NCT07388563
NCT06311227
NCT00106925
NCT06852222
NCT05376111
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions